Search Results

biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC

biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC).

February 5, 2024

·

4 min read

biomodal Files Patent Infringement Lawsuit Against New England Biolabs

July 2, 2024

·

2 min read

Press Releases

biomodal to Present New 6-Base Genome Data Showing Enhanced Sensitivity for Detection of Stage I Colorectal Cancer in Plasma cell-free DNA at American Society of Human Genetics Meeting 2024

November 4, 2024

·

3 min read

BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample.

April 13, 2023

·

6 min read

Press Releases

Brinter AM Technologies will provide a 3D bioprinter for Advanced Tissue Manufacturing capabilities at the International Space Station (ISS) for an ESA project.

With a commitment to foster space exploration and terrestrial benefits through human spaceflight activities, ESA is investigating microgravity’s effects on human tissue to develop solutions that keep astronauts healthy during long-term missions and improve Life on Earth.

August 29, 2024

·

3 min read

Press Releases

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

November 5, 2024

·

19 min read

Biotechnology Instruments Market Size To Hold USD 128.4 Billion By 2032

The global biotechnology instruments market size was exhibited at USD 87.16 billion in 2022 and it is expected to hold around USD 128.4 billion by 2032, growing at a CAGR of 3.95% from 2023 to 2032.

December 19, 2023

·

7 min read

Business

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.

May 8, 2024

·

32 min read

Business

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.

February 9, 2024

·

30 min read

Business

Catalent, Inc. Reports Preliminary First Quarter Fiscal 2024 Results and Reaffirms Full-Year Fiscal 2024 Guidance

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced preliminary financial results for the first quarter of fiscal 2024, which ended September 30, 2023.

November 15, 2023

·

26 min read